N
Nehad M. Ayoub
Researcher at Jordan University of Science and Technology
Publications - 73
Citations - 1535
Nehad M. Ayoub is an academic researcher from Jordan University of Science and Technology. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 19, co-authored 66 publications receiving 1093 citations. Previous affiliations of Nehad M. Ayoub include University of Louisiana at Monroe & University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Mohamed R. Akl,Poonam Nagpal,Nehad M. Ayoub,Betty Tai,Sathyen A. Prabhu,Catherine M. Capac,Matthew Gliksman,Andre Goy,K. Stephen Suh +8 more
TL;DR: This review focuses on the prognostic significance of FGF2 in cancer with emphasis on therapeutic intervention strategies for solid and hematological malignancies.
Journal ArticleDOI
Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models.
Mohamed R. Akl,Nehad M. Ayoub,Mohamed M. Mohyeldin,Belnaser A. Busnena,Ahmed I. Foudah,Yong-Yu Liu,Khalid A. Ei Sayed +6 more
TL;DR: The findings of this study suggest that (-)-oleocanthal is a promising dietary supplement lead with potential for therapeutic use to control malignancies with aberrant c-Met activity.
Journal ArticleDOI
Protein calorie malnutrition, nutritional intervention and personalized cancer care
Anju Gangadharan,Sung-Eun Choi,Ahmed Hassan,Nehad M. Ayoub,Gina Durante,Sakshi Balwani,Young Hee Kim,Andrew L. Pecora,Andre Goy,K. Stephen Suh +9 more
TL;DR: Cancer patients often experience weight loss caused by protein calorie malnutrition during the course of the disease or treatment, and with a chronic illness on board even a small amount of weight loss can open the door to cachexia.
Journal ArticleDOI
Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications
TL;DR: The ability of AuNPs to alter vasculature has captured recent attention in medical literature as potential therapeutic agents for the management of pathologic angiogenesis.
Journal ArticleDOI
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
TL;DR: The immune microenvironment of HER2-positive breast cancer is described and recent clinical advances of immunotherapeutic treatments in this breast cancer subtype are summarized and rationale and ongoing clinical evidence to the use of immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy are provided.